BRPI0918580A8 - Polimorfo cristalino b da n-(2-aminofenil)-4-[n-(piridina3-il)metóxi-carbonilaminometil]-benzamida, composição e combinação contendo o mesmo, uso e seu processo de produção - Google Patents
Polimorfo cristalino b da n-(2-aminofenil)-4-[n-(piridina3-il)metóxi-carbonilaminometil]-benzamida, composição e combinação contendo o mesmo, uso e seu processo de produçãoInfo
- Publication number
- BRPI0918580A8 BRPI0918580A8 BRPI0918580A BRPI0918580A BRPI0918580A8 BR PI0918580 A8 BRPI0918580 A8 BR PI0918580A8 BR PI0918580 A BRPI0918580 A BR PI0918580A BR PI0918580 A BRPI0918580 A BR PI0918580A BR PI0918580 A8 BRPI0918580 A8 BR PI0918580A8
- Authority
- BR
- Brazil
- Prior art keywords
- aminophenyl
- benzamide
- carbonylaminomethyl
- pyridine
- methoxy
- Prior art date
Links
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
POLIMORFO CRISTALINO B DA N-(2-AMINOFENIL)-4-[N-(PIRIDINA-3-IL)METÓXI-CARBONILAMINOMETIL]- BENZAMIDA, COMPOSIÇÃO E COMBINAÇÃO CONTENDO O MESMO, USO E SEU PROCESSO DE PRODUÇÃO. A presente invenção descreve o polimorfo cristalino B da N-(2-aminofeni|)-4-[N-(piridina-3-il)metóxi-carbonilaminometil]benzamida (MS-275) de fórmula I, assim como o processo para a produção do referido composto, e seu uso como um medicamento para o tratamento de doenças selecionadas.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9304608P | 2008-08-29 | 2008-08-29 | |
EP08163274.7 | 2008-08-29 | ||
US61/093,046 | 2008-08-29 | ||
EP08163274 | 2008-08-29 | ||
PCT/EP2009/006381 WO2010022988A1 (en) | 2008-08-29 | 2009-08-27 | N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275)polymorph b |
Publications (4)
Publication Number | Publication Date |
---|---|
BRPI0918580A2 BRPI0918580A2 (pt) | 2015-12-01 |
BRPI0918580A8 true BRPI0918580A8 (pt) | 2017-07-11 |
BRPI0918580B1 BRPI0918580B1 (pt) | 2020-11-24 |
BRPI0918580B8 BRPI0918580B8 (pt) | 2021-05-25 |
Family
ID=41133825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0918580A BRPI0918580B8 (pt) | 2008-08-29 | 2009-08-27 | polimorfo cristalino b da n-(2-aminofenil)-4-[n-(piridina3-il)metóxi-carbonilaminometil]-benzamida, composição e combinação contendo o mesmo, uso e seu processo de produção |
Country Status (36)
Country | Link |
---|---|
US (2) | US7973166B2 (pt) |
EP (1) | EP2350005B1 (pt) |
JP (1) | JP4921616B2 (pt) |
KR (1) | KR101073760B1 (pt) |
CN (1) | CN102137846B (pt) |
AR (1) | AR073226A1 (pt) |
AT (1) | ATE538094T1 (pt) |
AU (1) | AU2009286982C1 (pt) |
BR (1) | BRPI0918580B8 (pt) |
CA (1) | CA2735294C (pt) |
CO (1) | CO6351736A2 (pt) |
CR (2) | CR20110107A (pt) |
CY (1) | CY1112645T1 (pt) |
DK (1) | DK2350005T3 (pt) |
DO (1) | DOP2011000064A (pt) |
EA (1) | EA016811B1 (pt) |
EC (1) | ECSP11010849A (pt) |
ES (1) | ES2378640T3 (pt) |
HK (1) | HK1160107A1 (pt) |
HN (1) | HN2011000609A (pt) |
HR (1) | HRP20120183T8 (pt) |
IL (1) | IL211276A (pt) |
MA (1) | MA32610B1 (pt) |
MX (1) | MX2011002248A (pt) |
MY (1) | MY149058A (pt) |
NZ (1) | NZ591387A (pt) |
PE (2) | PE20110677A1 (pt) |
PL (1) | PL2350005T3 (pt) |
PT (1) | PT2350005E (pt) |
RS (1) | RS52164B (pt) |
SI (1) | SI2350005T1 (pt) |
SM (1) | SMT201200026B (pt) |
SV (1) | SV2011003846A (pt) |
TW (1) | TWI427062B (pt) |
WO (1) | WO2010022988A1 (pt) |
ZA (1) | ZA201102285B (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY149058A (en) | 2008-08-29 | 2013-07-15 | Bayer Ip Gmbh | N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275) polymorph b |
US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
FR2977492B1 (fr) * | 2011-07-04 | 2013-07-05 | Servier Lab | Nouvelle association entre le n-hydroxy-4-{2-[3-(n,n-dimethylaminomethyl) benzofuran-2-ylcarbonylamino]ethoxy}benzamide et le folfox |
UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
CA2966905A1 (en) | 2014-11-12 | 2016-05-19 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
EP3168210A1 (en) | 2015-11-13 | 2017-05-17 | Sandoz Ag | Crystalline forms of entinostat |
WO2017216761A1 (en) * | 2016-06-17 | 2017-12-21 | Dr. Reddy's Laboratories Limited | Solid forms of entinostat |
US11208382B2 (en) | 2017-07-28 | 2021-12-28 | Hangzhou Solipharma Co., Ltd. | Entinostat-containing compound, crystal form of compound thereof, and preparation method therefor and pharmaceutical composition thereof |
KR20240019100A (ko) | 2021-05-10 | 2024-02-14 | 맥파란 스미스 리미티드 | 엔티노스타트의 신규 형태 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6174905B1 (en) * | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
JP3354090B2 (ja) * | 1996-09-30 | 2002-12-09 | シエーリング アクチエンゲゼルシャフト | 分化誘導剤 |
JP4030683B2 (ja) * | 1998-07-24 | 2008-01-09 | 三井化学株式会社 | ベンズアミド誘導体の合成法 |
US6320078B1 (en) * | 1998-07-24 | 2001-11-20 | Mitsui Chemicals, Inc. | Method of producing benzamide derivatives |
JP2001064177A (ja) * | 1999-08-16 | 2001-03-13 | Schering Ag | ベンズアミド誘導体を有効成分とする製剤 |
JP4360660B2 (ja) * | 1999-11-09 | 2009-11-11 | 三井化学株式会社 | モノアシルフェニレンジアミン誘導体の精製法 |
PE20050206A1 (es) * | 2003-05-26 | 2005-03-26 | Schering Ag | Composicion farmaceutica que contiene un inhibidor de histona deacetilasa |
MY149058A (en) | 2008-08-29 | 2013-07-15 | Bayer Ip Gmbh | N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275) polymorph b |
-
2009
- 2009-08-27 MY MYPI2011000789A patent/MY149058A/en unknown
- 2009-08-27 CA CA 2735294 patent/CA2735294C/en active Active
- 2009-08-27 AT AT09778301T patent/ATE538094T1/de active
- 2009-08-27 ES ES09778301T patent/ES2378640T3/es active Active
- 2009-08-27 RS RSP20120083 patent/RS52164B/en unknown
- 2009-08-27 PT PT09778301T patent/PT2350005E/pt unknown
- 2009-08-27 WO PCT/EP2009/006381 patent/WO2010022988A1/en active Application Filing
- 2009-08-27 SI SI200930182T patent/SI2350005T1/sl unknown
- 2009-08-27 PL PL09778301T patent/PL2350005T3/pl unknown
- 2009-08-27 PE PE2011000218A patent/PE20110677A1/es not_active Application Discontinuation
- 2009-08-27 KR KR1020117007131A patent/KR101073760B1/ko active IP Right Review Request
- 2009-08-27 CN CN200980134057.8A patent/CN102137846B/zh active Active
- 2009-08-27 PE PE2014000099A patent/PE20141062A1/es not_active Application Discontinuation
- 2009-08-27 EP EP20090778301 patent/EP2350005B1/en active Active
- 2009-08-27 AU AU2009286982A patent/AU2009286982C1/en active Active
- 2009-08-27 EA EA201100354A patent/EA016811B1/ru active IP Right Grant
- 2009-08-27 NZ NZ591387A patent/NZ591387A/en unknown
- 2009-08-27 JP JP2011524272A patent/JP4921616B2/ja active Active
- 2009-08-27 BR BRPI0918580A patent/BRPI0918580B8/pt active IP Right Grant
- 2009-08-27 DK DK09778301T patent/DK2350005T3/da active
- 2009-08-27 MX MX2011002248A patent/MX2011002248A/es active IP Right Grant
- 2009-08-28 US US12/549,458 patent/US7973166B2/en not_active Ceased
- 2009-08-28 AR ARP090103317 patent/AR073226A1/es unknown
- 2009-08-28 TW TW098129170A patent/TWI427062B/zh active
-
2011
- 2011-02-17 IL IL211276A patent/IL211276A/en active IP Right Grant
- 2011-02-28 SV SV2011003846A patent/SV2011003846A/es unknown
- 2011-02-28 DO DO2011000064A patent/DOP2011000064A/es unknown
- 2011-02-28 HN HN2011000609A patent/HN2011000609A/es unknown
- 2011-02-28 EC ECSP11010849 patent/ECSP11010849A/es unknown
- 2011-02-28 CO CO11024240A patent/CO6351736A2/es unknown
- 2011-02-28 CR CR20110107A patent/CR20110107A/es unknown
- 2011-03-04 MA MA33670A patent/MA32610B1/fr unknown
- 2011-03-28 ZA ZA2011/02285A patent/ZA201102285B/en unknown
-
2012
- 2012-01-11 HK HK12100290.3A patent/HK1160107A1/xx unknown
- 2012-02-24 HR HRP20120183AT patent/HRP20120183T8/hr unknown
- 2012-03-20 CY CY20121100293T patent/CY1112645T1/el unknown
- 2012-06-01 SM SM201200026T patent/SMT201200026B/it unknown
-
2014
- 2014-03-07 US US14/201,684 patent/USRE45499E1/en active Active
-
2016
- 2016-08-27 CR CR20160465A patent/CR20160465A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0918580A8 (pt) | Polimorfo cristalino b da n-(2-aminofenil)-4-[n-(piridina3-il)metóxi-carbonilaminometil]-benzamida, composição e combinação contendo o mesmo, uso e seu processo de produção | |
BR112014005468A2 (pt) | derivados de aminopiridina para uso como moduladores de atividade quinase | |
BR112014031375A2 (pt) | moduladores da série de reação complementar e usos dos mesmos | |
CY1112429T1 (el) | Υποκατεστημενα παραγωγα σουλφοναμιδιου | |
DOP2011000102A (es) | Compuestos heteroaromaticos espirociclicos fusionados para el tratamiento de infecciones bacterianas | |
BR112013017316A2 (pt) | compostos de indol ou análogos dos mesmos para o tratamento de degeneração macular relacionada à idade (amd) | |
CR20130588A (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2 | |
BRPI0916735B8 (pt) | compostos moduladores de tgr5, composições farmacêuticas compreendendo os mesmos e seus usos | |
NO20090173L (no) | Kondensert spiroketalderivat og anvendelse derav som legemiddel for a behandle diabetes | |
EA201500182A1 (ru) | 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ | |
TN2013000413A1 (en) | Glycoside derivatives and their uses for the treatment of diabetes | |
BR112014003079A2 (pt) | derivado de 1,2,3,4-tetra-hidroquinolina útil para o tratamento de diabetes | |
BR112013000254A2 (pt) | derivados heterocíclicos 1-fenil-substituídos e seu uso como moduladores do receptor de prostaglandina d2 | |
BRPI0820668A2 (pt) | Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina | |
UA109290C2 (uk) | Спільні кристали і солі інгібіторів ccr3 | |
BR112014005554A2 (pt) | aminas de imidazol como moduladores de atividade de quinase | |
MX2011013869A (es) | Agentes antihelminticos y su uso. | |
UY35685A (es) | Compuestos de dióxido de amino tiazina bicíclicos puenteados como inhibidores de beta-secretasa y sus métodos de uso | |
CU20120087A7 (es) | Procedimiento de síntesis y forma cristalina del hidrocloruro de 4-(3-(cis-hexahidrociclopenta(c)pirrol-2(1h)-il)propoxi)benzamida así como las composiciones farmacéuticas que la contienen | |
BR112015006243A2 (pt) | agentes antibacterianos de fenicol | |
BRPI0507745A (pt) | compostos de azetidina substituìda como inibidores de ciclooxigenase-1-ciclooxigenase-2, processo para a sua preparação, medicamentos e seus usos | |
CU20110044A7 (es) | Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il)metoxicarbonilamino-metil]benzamida (ms-275) | |
UA98884C2 (en) | N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275) polymorph b | |
TN2011000091A1 (en) | N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275)polymorph b | |
BR112015011849A2 (pt) | método de preparação de formas de cristal de 4 (ciclopropilmetoxi)-n-(3,5-dicloro-1-oxidopiridin-4-il)-5-metoxipiridina-2-carboxamida e formas de cristal da mesma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: BAYER PHARMA AKTIENGESELLSCHAFT (DE) |
|
B25A | Requested transfer of rights approved |
Owner name: BAYER INTELLECTUAL PROPERTY GMBH (DE) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/11/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/08/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B25G | Requested change of headquarter approved |
Owner name: BAYER INTELLECTUAL PROPERTY GMBH (DE) |